The risk of heart-related issues accompanying the use of JAK inhibitors has brought the entire drug class under scrutiny
Last September, the FDA said it will require safety warnings for drugs such as Pfizer’s Xeljanz, Eli Lilly’s Olumiant and…
Technical Support